----item----
version: 1
id: {5DB9A336-AE53-45E6-84E8-2F6A8A13FB3E}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/09/06/Tevarsquos asthma drug reslizumab under FDA review
parent: {199B8802-DA9B-45D7-BE07-8E7DA944A744}
name: Tevarsquos asthma drug reslizumab under FDA review
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: 81f2c665-2b10-465e-8543-7281c2122057

----field----
field: {0212FC0F-953B-461C-B4D9-B7483A4D4F1B}
name: Taxonomy
key: taxonomy
content-length: 38

{F5161CC2-772F-472E-A21C-BF196343462E}
----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 52

Teva&rsquo;s asthma drug reslizumab under FDA review
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 50

Tevarsquos asthma drug reslizumab under FDA review
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 1295

<p>The FDA has assigned a standard review to Teva&rsquo;s biologic license application (BLA) for the firm&rsquo;s humanized monoclonal antibody reslizumab to treat inadequately controlled asthma in adults and adolescents with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based regimen.</p><p>The agency is expected to make a decision by March 2016.</p><p>Reslizumab&rsquo;s BLA is based on data from Teva&rsquo;s BREATH clinical program, which consisted of four separate placebo-controlled Phase III trials involving more than 1,700 adults and adolescents.</p><p>The results of the studies demonstrated that reslizumab reduced asthma exacerbation rates by at least half and provided significant improvement in lung function and other secondary measures of asthma control when added to an existing ICS-based therapy, versus placebo. </p><p>Common adverse events in the reslizumab treatment group included worsening of asthma, nasopharyngitis, upper respiratory infections, sinusitis, influenza and headache and were comparable to placebo.</p><p>Teva noted that two anaphylactic reactions were reported, but were resolved following medical treatment at the study site. </p><p>Shares of Teva closed at $60.68 on 15 June, down 95 cents, or 1.5%.</p><p><p><p><p><p><p><p><p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 312

<p>The FDA has assigned a standard review to Teva&rsquo;s biologic license application (BLA) for the firm&rsquo;s humanized monoclonal antibody reslizumab to treat inadequately controlled asthma in adults and adolescents with elevated blood eosinophils, despite an inhaled corticosteroid (ICS)-based regimen.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 50

Tevarsquos asthma drug reslizumab under FDA review
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20150906T234756
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20150906T234756
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20150906T234756
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC028993
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 52

Teva&rsquo;s asthma drug reslizumab under FDA review
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{185C14A2-61E1-460C-96C2-EB0D8AB963B0}
----field----
field: {AE1BD751-D4E7-49CB-96C4-62E995A06B51}
name: Article Category
key: article category
content-length: 11

Expert View
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

358869
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042404Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

81f2c665-2b10-465e-8543-7281c2122057
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042404Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
